Histone deacetylase inhibitors that increase histone acetylation on transformed cells are being investigated as unique anticancer drugs. The aim of this investigation was to evaluate an antiproliferative activity of the histone deacetylase inhibitors sodium butyrate (NaBT) and trichostatin A on 5 glioma cell lines, T98G, A172, U-87 MG, U-118 MG, and U-373 MG, with the examination of the altered...

Histone deacetylases are set of enzymes that have been of interest in drug discovery for the last more than 3 decades. They are responsible for cleaving of acetyl groups from acetyl-lysine residues in histones and various non-histone proteins. Histone deacetylase inhibition is a contemporary, clinically validated therapeutic tactic for cancer treatment. Hydroxamic acid derivatives are among the...